Pradžia › Vilkligė
Vilkligė klinikiniai tyrimai JAV ieško dalyvių
73 tyrimai dėl Vilkligė ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- New York City, NY18 tyrimai
- Houston, TX13 tyrimai
- Durham, NC12 tyrimai
- Washington, DC10 tyrimai
- Miami, FL10 tyrimai
- Tampa, FL9 tyrimai
- Philadelphia, PA9 tyrimai
- Clearwater, FL8 tyrimai
- Santa Monica, CA8 tyrimai
- Oklahoma City, OK8 tyrimai
- Boston, MA8 tyrimai
- Los Angeles, CA8 tyrimai
- Chicago, IL8 tyrimai
- Memphis, TN7 tyrimai
- Buena Park, CA7 tyrimai
- San Diego, CA7 tyrimai
- Charlotte, NC7 tyrimai
- Plantation, FL7 tyrimai
- Hollywood, FL6 tyrimai
- Aurora, CO6 tyrimai
- Dallas, TX6 tyrimai
- Cedar Rapids, IA6 tyrimai
- Atlanta, GA6 tyrimai
- Cicero, IL5 tyrimai
- Lake Charles, LA5 tyrimai
- Cleveland, OH5 tyrimai
- New Orleans, LA5 tyrimai
- Jackson, TN5 tyrimai
- Fullerton, CA5 tyrimai
- St. Louis, MO5 tyrimai
- Orlando, FL5 tyrimai
- Syracuse, NY5 tyrimai
- Coral Springs, FL4 tyrimai
- Allen, TX4 tyrimai
- Rochester, NY4 tyrimai
- Arlington, TX4 tyrimai
- Flint, MI4 tyrimai
- Phoenix, AZ4 tyrimai
- Louisville, KY4 tyrimai
- Brandon, FL4 tyrimai
Pagal valstiją
- Ajova6 tyrimai
- Alabama5 tyrimai
- Arizona7 tyrimai
- Džordžija9 tyrimai
- Florida23 tyrimai
- Ilinoisas14 tyrimai
- Indianas4 tyrimai
- Kalifornija27 tyrimai
- Kanzasas5 tyrimai
- Kentukis4 tyrimai
- Koloradas8 tyrimai
- Kolumbijos apskritis5 tyrimai
- Luiziana9 tyrimai
- Masčusetsas9 tyrimai
- Merilendas10 tyrimai
- Minesota5 tyrimai
- Misūris8 tyrimai
- Mičiganas10 tyrimai
- Nebraska3 tyrimai
- New Jersey6 tyrimai
- New York26 tyrimai
- North Carolina20 tyrimai
- Ohio11 tyrimai
- Oklahoma8 tyrimai
- Pennsylvania14 tyrimai
- South Carolina5 tyrimai
- Tennessee13 tyrimai
- Texas26 tyrimai
- Utah4 tyrimai
- Virginia3 tyrimai
- Washington5 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Renkami dalyviai3 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06617325Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT05268289A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07409181Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Renkami dalyviai3 fazė
Amžius nuo 12 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Renkami dalyviai3 fazė
Amžius nuo 5 iki 17 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05835310Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 120 · Moterims · Atnaujinta 2026-09-28 · NCT05567198A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Renkami dalyviai1 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07607964CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Renkami dalyviai1/2 fazė
Amžius nuo 10 iki 29 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06839976Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345Anifrolumab Pregnancy Study
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 130 · Moterims · Atnaujinta 2026-09-18 · NCT07049653The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-18 · NCT05440422Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Renkami dalyviai1 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-18 · NCT07201558A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Renkami dalyviai2 fazė
Amžius nuo 16 iki 70 · Visoms lytims · Atnaujinta 2026-09-17 · NCT07328581Transcutaneous Vagus Nerve Stimulation in SLE
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06987565Study of Systemic Lupus Erythematosus
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 3 iki 120 · Visoms lytims · Atnaujinta 2026-09-16 · NCT00001372HEALTH Home Urinalysis Testing
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT07823478Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
Renkami dalyviai4 fazė
Amžius nuo 18 iki 130 · Moterims · Atnaujinta 2026-09-16 · NCT06594068A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-15 · NCT06916806Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Renkami dalyviai1 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-09-14 · NCT06975787A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-14 · NCT07355218A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Renkami dalyviai2 fazė
Amžius nuo 12 iki 70 · Visoms lytims · Atnaujinta 2026-09-14 · NCT07570862A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-11 · NCT07332481A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-10 · NCT06897930Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.